Key facts
- This page summarizes Steven B. Ratoff's Form 4 filing for EAGLE PHARMACEUTICALS, INC. (EGRX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Mar 2023, 20:04.
Steven B. Ratoff - 07 Mar 2023 Form 4 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)
- Reporting relationship
- Director
- Issuer ticker
- EGRX
- Reported as of
- 07 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Mar 2023, 20:04:45 UTC
- Prior SEC filing
- 02 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Scott Tarriff, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Steven B. Ratoff filed Form 4 for EAGLE PHARMACEUTICALS, INC. (EGRX) on 09 Mar 2023.
Change
- Previous filing in this sequence was filed on 02 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EGRX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +16,253
- Change %
- Price
- $0.000000
- Shares after
- 16,253
- Date
- 07 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,253
- Exercise price
- $26.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option fully vests on March 7, 2024, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.